DNA polymerase Inhibitors
3 drugsAbout DNA polymerase
DNA polymerase is a crucial enzyme involved in DNA replication and repair in all living organisms. It synthesizes new DNA strands using existing strands as templates, ensuring accurate duplication of genetic information. Its fundamental role makes it a significant target for drug development.
Currently, there is no genetic evidence directly linking DNA polymerase variations to specific diseases. However, its fundamental role in cell division and survival makes it a compelling target, particularly in rapidly dividing cells such as cancer cells.
Three FDA-approved drugs target DNA polymerase: VYXEOS, MULTRYS, and TRALEMENT. These drugs are all small molecules and are developed by AM REGENT and JAZZ PHARMS THERAP for oncology and other indications.
Strategic Insights
ℹ️ How we calculate- phase2 represents biological uncertainty with 47% completion.
Top DNA polymerase Drugs
The competitive landscape is dominated by AM REGENT and JAZZ PHARMS THERAP.
High market concentration suggests potential entry barriers for new companies.
DNA polymerase Drug Modality Landscape
Modalities
Routes of Administration
DNA polymerase is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or PROTACs may offer a competitive advantage.
DNA polymerase Clinical Trials 631 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 257 | 116 | 73 | 67 | 61% |
| Phase 2 | 279 | 94 | 55 | 126 | 63% |
| Phase 3 | 87 | 29 | 11 | 45 | 73% |
| Phase 4 | 8 | 3 | 2 | 3 | 60% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
4 Phase 3 trials testing approved DNA polymerase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting DNA polymerase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
DNA polymerase Drug Approval Timeline (2017 - 2020)
The first drug was approved in 2017, and the most recent in 2020, spanning 4 years.
Recent approvals suggest continued interest, but a short timespan may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 426 clinical trials targeting DNA polymerase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities